Detailed description of which diseases and tumor types Axitinib (Inlida) mainly treats

Axitinib (Axitinib, trade name: Inlyta) is an oral small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine Kinase inhibitors inhibit tumor angiogenesis by blocking the VEGFR-1, VEGFR-2 and VEGFR-3 signaling pathways, thereby inhibiting tumor growth and metastasis. It is classified as a targeted anti-angiogenic drug and is one of the important options for the treatment of various solid tumors.

The main indication for axitinib is advanced or metastatic clear cell renal cell carcinoma (RCC). In first- or second-line treatment, axitinib can be used in patients who are resistant to drugs such as immune checkpoint inhibitors or sorafenib. Clinical studies have shown that axitinib can significantly prolong progression-free survival (PFS) and improve objective response rate (ORR), providing a reliable targeted therapy for patients with advanced renal cancer.

In addition to renal cancer, axitinib has also carried out relevant clinical studies in thyroid cancer, non-small cell lung cancer (NSCLC) and other solid tumors. Especially in patients with thyroid cancer refractory to radioactive iodine, axitinib has shown an effective inhibitory effect on tumor growth. In addition, it also shows certain anti-tumor activity in some solid tumors with overexpression of VEGFR, providing a basis for future expansion of indications.

The advantages of axitinib are oral administration, strong targeting, controllable side effects, and suitable for long-term maintenance treatment. In clinical practice, doctors will develop individualized treatment plans based on the patient's tumor type, previous treatment history, and tolerance. In advanced renal cancer and some VEGFR-dependent tumors, axitinib not only delays disease progression, but also improves patients' quality of life, making it an important part of modern targeted tumor therapy.

Reference materials:https://www.drugs.com/